FTC Wins Dismissal Of Opana, Lidoderm Pay-For-Delay Suit
A Pennsylvania federal judge granted the U.S. Federal Trade Commission's request to dismiss its pay-for-delay suit against Endo Pharmaceuticals Inc. over pain drugs Opana ER and Lidoderm on Tuesday after Endo...To view the full article, register now.
Already a subscriber? Click here to view full article